MoonLake Immunotherapeutics (MLTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MoonLake Immunotherapeutics (MLTX) trades at $18.56 with AI Score 49/100 (Grade C). MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. Market cap: $1.37B, Sector: Healthcare.
Price live · AI analysis from May 9, 2026MLTX stock analysis for 2026: Analysts have set a consensus price target of $29.20 for MoonLake Immunotherapeutics, suggesting 57.3% upside from the current price of $18.56. The AI MoonshotScore is 49/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
MLTX: the 1 perspectives are evenly split.
How is this calculated? →MoonLake Immunotherapeutics (MLTX) Healthcare & Pipeline Overview
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, is focused on developing Sonelokimab, a novel Nanobody therapy targeting inflammatory diseases. The company is currently conducting Phase II trials across multiple indications, positioning it within the competitive biotechnology landscape focused on innovative immunology treatments.
What Is the Investment Thesis for MLTX?
MoonLake Immunotherapeutics presents a focused investment opportunity within the biotechnology sector, driven by the potential of Sonelokimab. The drug's ongoing Phase II trials across multiple indications, including hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis, represent significant near-term catalysts. Positive trial results could lead to further clinical development and eventual commercialization, driving substantial value. The company's market capitalization of $1.37B reflects investor expectations for Sonelokimab's success. However, the inherent risks of clinical-stage drug development, including trial failures and regulatory hurdles, must be considered. The company's success hinges on the successful completion of clinical trials and subsequent regulatory approvals.
Based on FMP financials and quantitative analysis
MLTX Key Highlights
- Market capitalization of $1.37B, reflecting current investor valuation of MoonLake's potential.
- Sonelokimab is in Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis.
- Beta of 1.19, indicating slightly higher volatility compared to the overall market.
- Focus on Nanobody technology offers a potentially differentiated approach to treating inflammatory diseases.
- Founded in 2021, MoonLake is a relatively young company with a focused pipeline.
Who Are MLTX's Competitors?
MLTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ERAS Erasca, Inc. | $18.59 | +0.64% | $5.78B | 71 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MLTX's Key Strengths?
- Novel Nanobody technology platform.
- Focused pipeline targeting specific inflammatory pathways.
- Experienced management team.
- Strong financial backing.
What Are MLTX's Weaknesses?
- Clinical-stage company with no approved products.
- Reliance on the success of Sonelokimab.
- Limited commercial infrastructure.
- High cash burn rate.
What Could Drive MLTX Stock Higher?
- Phase II trial results for Sonelokimab in hidradenitis suppurativa.
- Phase II trial results for Sonelokimab in psoriatic arthritis.
- Phase II trial results for Sonelokimab in ankylosing spondylitis.
- Phase II trial results for Sonelokimab in radiographic axial spondyloarthritis.
What Are the Key Risks for MLTX?
- Negative return on equity (-85.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Sonelokimab.
- Regulatory delays or rejection of Sonelokimab.
- Competition from established therapies and other companies developing treatments for inflammatory diseases.
- Dependence on securing additional funding to support clinical development.
What Are the Growth Opportunities for MLTX?
- Growth opportunity 1: Successful completion of Phase II trials for Sonelokimab across multiple indications represents a significant growth catalyst. Positive results could lead to Phase III trials and eventual regulatory approval, opening up a multi-billion dollar market opportunity in inflammatory disease treatment. The timeline for Phase II completion varies by indication, but initial results are expected within the next 12-24 months. MoonLake's competitive advantage lies in the potential efficacy and safety profile of Sonelokimab compared to existing therapies.
- Growth opportunity 2: Expansion of Sonelokimab's indications beyond the current Phase II trials could unlock further growth potential. Exploring its use in other inflammatory diseases, such as Crohn's disease or ulcerative colitis, could significantly broaden the market opportunity. This expansion would likely occur after demonstrating success in the current indications, with a timeline of 3-5 years. MoonLake's expertise in immunology and Nanobody technology provides a foundation for this expansion.
- Growth opportunity 3: Strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of Sonelokimab. Collaborations could provide access to additional funding, expertise, and distribution networks. The timing of such partnerships is uncertain, but typically occurs after positive Phase II results. MoonLake's attractive technology and focused pipeline make it a potential partner for companies seeking to expand their immunology portfolio.
- Growth opportunity 4: Potential for Orphan Drug Designation for Sonelokimab in specific indications could provide market exclusivity and other regulatory benefits. This designation is granted for drugs treating rare diseases, and could enhance the commercial attractiveness of Sonelokimab. The timeline for obtaining Orphan Drug Designation depends on the specific indication and regulatory review process. MoonLake's focus on targeted therapies increases the likelihood of qualifying for this designation.
- Growth opportunity 5: Geographic expansion into new markets, such as Asia and Latin America, could drive revenue growth. These regions have a growing prevalence of inflammatory diseases and increasing healthcare spending. The timeline for geographic expansion would likely follow regulatory approval in major markets such as the US and Europe, with a potential launch in new regions within 3-5 years. MoonLake's global headquarters in Switzerland positions it well for international expansion.
What Opportunities Does MLTX Have?
- Successful completion of Phase II trials.
- Expansion into new indications.
- Strategic partnerships with larger pharmaceutical companies.
- Orphan Drug Designation for specific indications.
What Threats Does MLTX Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established therapies.
- Patent challenges.
What Are MLTX's Competitive Advantages?
- Proprietary Nanobody technology platform.
- Patent protection for Sonelokimab and related therapies.
- Clinical data demonstrating efficacy and safety.
- Expertise in immunology and drug development.
What Does MLTX Do?
MoonLake Immunotherapeutics, founded in 2021 and headquartered in Zug, Switzerland, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for inflammatory diseases. The company's primary focus is on Sonelokimab, a novel investigational Nanobody designed to inhibit the IL-17A/A cytokine. This cytokine is a key driver of inflammation in various autoimmune diseases. Sonelokimab is currently undergoing Phase II clinical trials for several indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and radiographic axial spondyloarthritis (r-axSpA). These trials aim to evaluate the efficacy and safety of Sonelokimab in patients suffering from these chronic inflammatory conditions. The company's strategic approach involves targeting specific inflammatory pathways with the goal of providing more effective and targeted treatments compared to existing therapies. MoonLake's commitment to innovation and its focus on Nanobody technology differentiate it within the competitive biotechnology sector. The company is led by a team with experience in drug development and immunology, positioning it to potentially address unmet needs in the treatment of inflammatory diseases.
What Products and Services Does MLTX Offer?
- Develop novel therapies for inflammatory diseases.
- Focus on Nanobody technology for targeted drug delivery.
- Conduct Phase II clinical trials for Sonelokimab in multiple indications.
- Target the IL-17A/A cytokine, a key driver of inflammation.
- Seek to improve treatment options for patients with hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis.
- Advance clinical programs through strategic partnerships and collaborations.
How Does MLTX Make Money?
- Develop and patent novel therapeutic candidates.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA and EMA.
- Commercialize approved therapies directly or through partnerships.
What Industry Does MLTX Operate In?
MoonLake Immunotherapeutics operates within the biotechnology industry, which is characterized by high innovation, significant regulatory hurdles, and substantial financial investments. The market for inflammatory disease treatments is large and growing, driven by an aging population and increasing prevalence of autoimmune disorders. Competition is intense, with established pharmaceutical companies and other biotechnology firms vying for market share. MoonLake's focus on Nanobody technology and its specific targeting of the IL-17A/A cytokine position it as a potential disruptor in this competitive landscape.
Who Are MLTX's Key Customers?
- Patients suffering from inflammatory diseases.
- Healthcare providers who prescribe and administer treatments.
- Payers, including insurance companies and government healthcare programs.
F-Score 1/9Financial Health
MoonLake Immunotherapeutics's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.86 places it in the grey zone, a middle ground that warrants monitoring.
ROE -86%Key Financial Metrics
Return on equity for MoonLake Immunotherapeutics stands at -85.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -64.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -18.6%, the inverse of the P/E and a quick read on earnings relative to price.
MoonLake Immunotherapeutics (MLTX) Valuation Context
Valued at $1.37B, MLTX is classified as a small-cap stock. Relative to its peer group, MLTX's quantitative score of 49/100 is below the peer average of 76/100.
FY2026 estForward Outlook
Wall Street analysts project MoonLake Immunotherapeutics revenue of about $0 for fiscal 2026, with EPS near $-3.82.
MLTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- MoonLake's recent insider buying suggests those in the know see long-term potential, signaling confidence in the company's direction.
- Community sentiment indicates growing optimism surrounding MoonLake's clinical trial progress, fostering positive market perception.
- The company's focus on innovative immunology treatments positions them favorably in a high-growth sector, attracting investor interest. Think of it like Moderna riding the mRNA wave.
- Bullish community members highlight MoonLake's strong intellectual property portfolio as a key competitive advantage, protecting their innovations.
Bear Case
- Bearish community members express concerns about potential competition from larger pharmaceutical companies with deeper pockets.
- Recent market volatility has created an environment of risk aversion, potentially impacting MoonLake's stock performance, similar to what happened during the initial COVID-19 crash.
- Some investors worry about the regulatory hurdles and timelines associated with bringing new drugs to market, creating uncertainty around MoonLake's future revenue streams.
- Negative sentiment surfaces due to lack of news flow, sparking doubts about near-term catalysts and growth prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
MLTX Latest News
MLTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MLTX.
Price Targets
Consensus target: $29.20
MLTX MoonshotScore
What does this score mean?
The MoonshotScore rates MLTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jorge Santos da Silva
CEO
Jorge Santos da Silva is the Chief Executive Officer of MoonLake Immunotherapeutics, leading a team of 100 employees. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has a proven track record in drug development, commercialization, and strategic leadership. Prior to joining MoonLake, he held leadership positions at various pharmaceutical companies, where he oversaw the development and launch of multiple successful products. His expertise spans across various therapeutic areas, including immunology and inflammation.
Track Record: Since joining MoonLake Immunotherapeutics, Jorge Santos da Silva has focused on advancing the clinical development of Sonelokimab. Key milestones under his leadership include initiating Phase II trials across multiple indications and securing funding to support the company's research and development efforts. He has also been instrumental in building a strong team and fostering a culture of innovation within the company.
MoonLake Immunotherapeutics Healthcare Stock: Key Questions Answered
What does MoonLake Immunotherapeutics do?
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases. Their lead product, Sonelokimab, is a novel Nanobody therapy currently in Phase II clinical trials for multiple indications, including hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis. The company aims to address unmet needs in the treatment of these chronic inflammatory conditions by targeting the IL-17A/A cytokine, a key driver of inflammation.
What do analysts say about MLTX stock?
Analyst coverage of MoonLake Immunotherapeutics (MLTX) is focused on the potential of Sonelokimab and its ongoing Phase II clinical trials. Key valuation metrics include market capitalization and potential peak sales estimates for Sonelokimab. Growth considerations center on the successful completion of clinical trials, regulatory approvals, and commercialization. Analyst consensus reflects optimism regarding the company's prospects, but also acknowledges the inherent risks associated with clinical-stage biotechnology companies. No buy/sell recommendations are provided.
What are the main risks for MLTX?
The primary risks for MoonLake Immunotherapeutics include the potential for clinical trial failures, regulatory hurdles, and competition from established therapies. Clinical trial failures could significantly impact the company's valuation and future prospects. Regulatory delays or rejection of Sonelokimab could also hinder its commercialization. Competition from established therapies and other companies developing treatments for inflammatory diseases poses an ongoing challenge. Additionally, the company's dependence on securing additional funding to support clinical development represents a financial risk.
What is MoonLake Immunotherapeutics's drug pipeline status?
MoonLake Immunotherapeutics's primary focus is on the development of Sonelokimab, a Nanobody therapy. Currently, Sonelokimab is in Phase II clinical trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis. The company is focused on advancing these trials and reporting results. The successful completion of these trials is a key catalyst for the company, potentially leading to Phase III development and eventual regulatory approval. The company does not currently have other disclosed assets in its clinical pipeline.
How does MoonLake Immunotherapeutics navigate regulatory approval processes?
As a clinical-stage biopharmaceutical company, MoonLake Immunotherapeutics is focused on navigating the regulatory approval processes of agencies such as the FDA in the United States and the EMA in Europe. The company's strategy involves conducting rigorous clinical trials to demonstrate the safety and efficacy of Sonelokimab. They adhere to Good Clinical Practice (GCP) guidelines and maintain open communication with regulatory agencies. The company's regulatory track record is currently limited, as they have no approved products, but their future success depends on successfully navigating these regulatory pathways.
What are the key factors to evaluate for MLTX?
MoonLake Immunotherapeutics (MLTX) holds an AI score of 49/100 (low). Analysts target $29.20 (+57%). Not financial advice.
How frequently does MLTX data refresh on this page?
MLTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MLTX's recent stock price performance?
MoonLake Immunotherapeutics (MLTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel Nanobody technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.